Promises and caveats of in silico biomarker discovery by Pusztai, L & Leyland-Jones, B
Editorial
Promises and caveats of in silico biomarker discovery
L Pusztai*,1 and B Leyland-Jones
2
1Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston,
TX 77030-1439, USA;
2Emory University School of Medicine, Atlanta GA, 30322
British Journal of Cancer (2008) 99, 385–386. doi:10.1038/sj.bjc.6604495 www.bjcancer.com
& 2008 Cancer Research UK
                
Several biomarkers have been reported to be associated with
survival in breast cancer over the past decades. Unfortunately, it is
often difficult to distinguish between the prognostic and predictive
values of these proposed markers and independent validations are
frequently lacking. Patients with early-stage breast cancer receive
various combinations of treatments including surgery, post-
operative radiation therapy, adjuvant endocrine treatment and
chemotherapy. Each of these can have an impact on survival, and
most biomarker studies included heterogeneously treated patient
cohorts. The classical methodology of assessing the true prognostic
value of a marker was restricted to patients who underwent
local regional therapy alone and received no systemic adjuvant
treatment.
However, the clinical utility of such prognostic markers in the
absence of systemic therapy is limited in this era. Endocrine
sensitivity in newly diagnosed stage I–III breast cancer may be
best evaluated in patients who received adjuvant endocrine
treatment but no chemotherapy after surgery and the chemo-
therapy response predictive value of a marker may be best
examined in the preoperative treatment setting where tumour
response can be measured directly. Undoubtedly, the best samples
to assess interaction between markers and treatment outcome are
from randomized clinical trials that compare different treatment
modalities. Unfortunately, many such trials from the past with
good outcome data lack tumour banks: it is difficult to obtain
specimens from large cohorts of homogeneously treated patients
and specimens from randomized clinical trials are an even rarer
research commodity. This motivates systematic efforts to collect
biological specimens in cancer clinical trials today.
Traditional markers also require separate assays to be
performed for each marker on the limited tissue resources.
Therefore, it is not surprising that few prognostic or predictive
markers have completed the necessary validation steps on the right
type of clinical specimens to convince physicians about their
clinical value (Simon, 2005). In this issue of the journal, Epping
et al (2008) report on that PRAME mRNA expression is prognostic
in early-stage breast cancer. They observed that this gene had
higher expression in tumours that relapsed within 5 years in the
absence of systemic adjuvant therapy. The bimodal distribution of
PRAME expression offered an opportunity to define a natural
cutoff in the data to assign high or low expression status for cases
(for most biomarkers that show a near normal distribution,
defining optimal cutoff values to assign low or high expression
status is more difficult). In a second independent cohort of
patients, who also received no systemic adjuvant therapy
(n¼185), they confirmed that cancers with higher PRAME
expression had poorer survival. When PRAME expression was
correlated with survival in a third cohort of patients who received
adjuvant chemotherapy (n¼110), no association with outcome
was seen. This suggests that high PRAME expression is predictive
of poor prognosis in the absence of adjuvant chemotherapy, but is
also predictive of greater sensitivity to chemotherapy (ie poor
prognosis is no longer observed if patients receive adjuvant
chemotherapy). Markers with similar characteristics have been
reported previously including proliferative activity, histologic
grade or the Oncotype DX recurrence score.
Perhaps the most important feature of this article is that these
provocative observations were made entirely through in silico
analysis of publicly available gene expression data (that was
initially generated by these investigators), without any additional
experiments. In the past few years, a remarkable transformation
has begun to evolve in the biomarker field. Comprehensive high-
throughput genomic analytical tools including mRNA gene
expression profiling are increasingly applied to human cancers
in an attempt to discover predictors of clinical outcome. When the
main results from these studies are published, it is required by
most journals to make the genomic data public. An important
central repository for these data sets is the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo). Among many others,
there are now publicly available comprehensive gene expression
data sets from cohorts of breast cancers patients who did not
receive any systemic adjuvant therapy, as well as from oestrogen
receptor-positive patients who were treated with adjuvant endo-
crine therapy only, and from patients who received preoperative
chemotherapy.
These databases provide an unprecedented opportunity to
rapidly evaluate almost any mRNA expression-based marker
separately for prognostic, endocrine and chemotherapy response
predictive values in silico (Andre et al, 2007). Studies that used to
require many years to complete for immunohistochemistry-based
markers can now be completed in a few weeks by a well trained
investigator in basic bioinformatics methods. Not only can single
genetic markers be assessed, but also any number of combinations
of genes that might represent cellular regulatory pathways or other
molecular functions can be tested. The multiple data sets also
provide an opportunity for marker optimisation in one data set
and independent validation in others.
One important caveat to this approach is that results generated
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to validate the accuracy of clinical annotations. Technical noise
due to variable quality of measurements can be substantial and
systematic differences in the analytical methods including array
platforms and data normalisation can make comparisons across
data sets challenging. For these reasons, it is unlikely that any
biomarker discovered solely through in silico analysis would
gain wide clinical acceptance in the foreseeable future. This is a
preliminary approach to the value of the markers and future
studies should follow the reporting recommendations for tumour
marker prognostic studies (REMARK, McShane et al, 2005) and
standardised end points and events in clinical trials (STEEP, Hudis
et al, 2007). It is also important to consider that if the intended
clinical assay is different from the high throughput platform,
validation of the new assay (eg, PCR or immunochemistry) vs the
original microarray findings is necessary and inter- and intra-
assay variation should also be provided. Nevertheless, genomic
data sets and the rapidly expending bioinformatic tools to analyse
them provide a unique opportunity to quickly evaluate biomarker
concepts with minimal cost and identify promising markers
for prospective validation on precious, nonrenewable clinical
specimens.
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